Clinical Trial Update: Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL [Phase 1, Phase 2]

View source ↗

Summary

A pilot study evaluating the Btk inhibitor PCI-32765 (ibrutinib) effects on leukemia cell kinetics and trafficking in CLL/SLL using heavy water labeling; phases…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• PCI-32765 (ibrutinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-02-24